Patents Examined by Po-Chih Chen
  • Patent number: 11813235
    Abstract: Disclosed are methods for using guanfacine, an analog or derivative of guanfacine, or a pharmaceutically acceptable salt thereof, to reduce the virulence of a bacterial pathogen. When treating a patient, the method generally involves administering to the patient a therapeutically effective dose of guanfacine, an analog or derivative of guanfacine, or a pharmaceutically acceptable salt thereof. An alternative method involves contacting the bacterial pathogen with guanfacine, an analog or derivative of guanfacine, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: November 14, 2023
    Inventors: Mohammad R. Seyedsayamdost, Bethany K. Okada, Anran Li
  • Patent number: 11793782
    Abstract: The present disclosure provides for treating neurodegenerative diseases comprising administering leucine, acetyl-leucine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: October 24, 2023
    Assignee: IntraBio Limited
    Inventor: Mallory Factor
  • Patent number: 11773120
    Abstract: In the method for producing an optically active 2,3-bisphosphinopyrazine derivative of the present invention, an optically active 2,3-bisphosphinopyrazine derivative represented by the following formula (3) is produced by the step of: preparing solution A containing 2,3-dihalogenopyrazine represented by the following formula (1) and a carboxylic acid amide coordinating solvent, lithiating an optically active R- or S-isomer of a hydrogen-phosphine borane compound represented by the following formula (2) to give a lithiated phosphine borane compound; adding solution B containing the lithiated phosphine borane compound to the solution A to perform an aromatic nucleophilic substitution reaction; and then performing a deboranation reaction. (For symbols in the formulas, see the description.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: October 3, 2023
    Inventors: Daisuke Mayama, Satoshi Takeshita, Ken Tamura
  • Patent number: 11773121
    Abstract: A compound can include the structure of Formula 1, derivative thereof, prodrug thereof, salt thereof, stereoisomer thereof, tautomer thereof, polymorph thereof, or solvate thereof, or having any chirality at any chiral center: R1 includes a hydrogen or a substituent; R2 includes a hydroxyl, hydroxyl-forming prodrug, or hydroxyl-leaving chemical moiety; R3 includes a halogen; and R4 includes a heterocycle. The compound can be an antiviral compound used in antiviral therapies.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: October 3, 2023
    Assignee: VIROVAX LLC
    Inventors: Sunil Abraham David, Naveen Kumar Rayala
  • Patent number: 11760715
    Abstract: The present invention relates to modulators of lipoxygenase and/or cyclooxygenase enzyme. The present invention also provides compositions comprising such modulators, and methods therewith for treating lipoxygenase receptor mediated diseases.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: September 19, 2023
    Assignee: Université de Moncton
    Inventors: Mohamed Touaibia, Marc Edgar Surette
  • Patent number: 11753406
    Abstract: The present invention relates to salt forms of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2?-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, including methods of preparation thereof, where the compound is useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: September 12, 2023
    Assignee: Incyte Corporation
    Inventors: Zhongjiang Jia, Pingli Liu, David J. Meloni, Yongchun Pan, Yongzhong Wu, Jiacheng Zhou, Qun Li
  • Patent number: 11746116
    Abstract: The invention relates to antibiotic compounds of formula (A1) and pharmaceutically acceptable salts, solvates, tautomers and combinations thereof, wherein X and L are optional linkers and one of RA or R1 comprises Ar1, wherein Ar1 is an antibiotic resistance breaker moiety which comprises an optionally substituted C6-10 aryl, C7-13 aralkyl, C5-10 heteroaryl, C6-13 heteroaralkyl, C5-10 heterocyclyl, C6-13 heterocyclalkyl, C3-10 carbocyclyl, C4-13 carbocyclalkyl, —C(?NR?)—NR?R? or —CH2—CH?CH2 group; wherein after administration of the compound to a bacterial infection this moiety reduces or prevents efflux. The invention also discloses pharmaceutical compositions comprising compounds of formula (A1) and the use of such compounds as medicaments, in particular, to treat bacterial infections, such as drug-resistant bacterial infections.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: September 5, 2023
    Assignees: King's College London, Secretary of State for Health and Social Care
    Inventors: Khondaker Mirazur Rahman, Shirin Jamshidi, Mark Benjamin Laws, Kazi Nahar, John Mark Sutton, Charlotte Hind
  • Patent number: 11746120
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 10, 2022
    Date of Patent: September 5, 2023
    Assignee: Kymera Therapeutics, Inc.
    Inventors: Nello Mainolfi, Nan Ji, Bin Yang, Yi Zhang
  • Patent number: 11731966
    Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: August 22, 2023
    Inventors: Kiran Reddy, Andrew Mark Griffin, Brian Edward Marron, Gabriel Martinez Botella
  • Patent number: 11725138
    Abstract: The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound according to the present disclosure, it is possible to provide an organic electroluminescent device having improved driving voltage, luminous efficiency, lifetime and/or power efficiency properties.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: August 15, 2023
    Inventors: Hyun Kim, Ji-Won Um, Kyoung-Jin Park, Mi-Ja Lee, Chi-Sik Kim
  • Patent number: 11708322
    Abstract: Disclosed herein a process preparation of 2,6-dichlorobenzonitrile. A process of making high yield, high purity 2,6-dichlorobenzonitrile including the selective de-nitrochlorination of 2-chloro-6-nitrobenzonitrile by treatment of the 2-chloro-6-nitrobenzonitrile with chlorine gas.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: July 25, 2023
    Inventors: Kamal Kataria, Vic Prasad, Christopher Lynn Larson, Cameron Seath Gibb, Kirit Desai, Ashwani Gupta, Girish Sisode
  • Patent number: 11691980
    Abstract: A method of treating a disease that is treatable through inhibition of at least one kinase selected from the group consisting of CDK7, CDK4, CDK6, PIM2, TSSK3, MST4, NEK6, MAP3K, MST3, DDR1, SPHK1, CaMK1, AurA, BRK, CaMK4, and PIM1, the method comprising administering an effective dose of a compound represented by the following formula (1) or a salt thereof to a patient:
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: July 4, 2023
    Inventors: Ken Saijo, Chikashi Ishioka, Tadashi Katoh, Koichi Narita
  • Patent number: 11690813
    Abstract: Members of the PrC-210 family of aminothiols, including PrC-211 and PrC-252, are shown to be highly effective in reducing ischemia-reperfusion injury in two preclinical models, including kidney transplant and myocardial infarct. Compositions and methods employing members of the PrC-210 family of aminothiols are disclosed for suppressing ischemia-reperfusion-induced cell and organ toxicities in a number of settings, significantly including organ transplant and myocardial infarct.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: July 4, 2023
    Inventors: William E. Fahl, Ningfeng Li
  • Patent number: 11691953
    Abstract: The present invention provides compounds as PPAR agonists and their application, involving a new class of peroxisome proliferator-activated receptor (PPAR) gamma receptor agonist, which can inhibit the production of mitochondrial reactive oxygen species, and most of which can readily cross the blood-brain barrier. The present invention also includes pharmaceutical uses of the compounds.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: July 4, 2023
    Inventors: Lihai Zhang, Min Hu
  • Patent number: 11691992
    Abstract: This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: July 4, 2023
    Assignees: Anacor Pharmaceuticals, Inc., The Government of the United States, as represented by the Secretary of the Army
    Inventors: Robert Toms Jacobs, Yang Liu, Richard J. Sciotti, Jason D. Speake, Gavin Alistair Whitlock, Paul Alan Glossop, Charles Eric Mowbray, Delphine Françoise Monique Launay, Stephen John Robinson
  • Patent number: 11667618
    Abstract: The present disclosure provides an azulene ring-containing compound, its use, and an organic photoelectric device including the same. The azulene ring-containing compound is a compound comprising a structure of Formula I. The organic photoelectric device includes an anode, a cathode, and one or more organic thin film layers located between the anode and the cathode; and at least one of the organic thin film layers contains the above-mentioned azulene ring-containing compound comprising the structure of Formula I. The azulene ring-containing compound provided by the present disclosure has an energy level difference ?Est?0.3 eV between the lowest singlet state S1 and the lowest triplet state T1, and has a light-emitting mechanism of a thermally activated delayed fluorescent material, and can be used as a thermally activated delayed fluorescent material for organic photoelectric device, so that the light-emitting efficiency of the device is improved.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: June 6, 2023
    Assignee: Wuhan Tianma Micro-Electronics Co., Ltd.
    Inventors: Tiezhen Gao, Wei Gao, Jinghua Niu
  • Patent number: 11667631
    Abstract: The present invention relates to an FGFR4 inhibitor having a structure represented by formula (I), preparation method therefor, and applications thereof. A series of compounds represented by formula (I) in the present invention have very-strong inhibition effect on the activity of FGFR4 kinase, have very-high selectivity, can be widely used in the preparation of drugs for treating cancers, specially a liver cancer, a stomach cancer, a prostate cancer, a skin cancer, an ovarian cancer, a lung cancer, a breast cancer or a colon cancer, and can be developed into a new-generation FGFR4 inhibitor drug.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: June 6, 2023
    Assignees: Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Shanghai Hansoh Biomedical Co., Ltd.
    Inventors: Peng Gao, Wenhua Xiu, Shaobao Wang, Lei Liu, Rudi Bao
  • Patent number: 11661407
    Abstract: The present invention relates to the process for the preparation of Pyrylium salts having the formula represented below. Present invention provide a simplified method of producing symmetrical and unsymmetrical pyrylium salts. The invention explores readily available starting materials with reaction conditions which are suitable for industrial scale applications. All the synthesized compounds were confirmed by various spectroscopic techniques such as Fourier transform infrared spectroscopy, 1H NMR, 13C NMR, 19F NMR spectroscopy, and single-crystal X-ray analysis. Mass of the compounds confirmed by HRMS analysis.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: May 30, 2023
    Inventors: Sasidhar Balappa Somappa, Chettiyan Thodi Fathimath Salfeena, Ayyappanpillai Ajayaghosh
  • Patent number: 11660287
    Abstract: An object of the present invention is to provide an excellent drug for preventing or treating spinocerebellar ataxia. 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of suppressing brain atrophy, especially cerebellar atrophy, and is useful as an agent for preventing or treating spinocerebellar ataxia. Cerebellar atrophy observed in spinocerebellar ataxia can be prevented or treated by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: May 30, 2023
    Assignee: FUJIFILM Toyama Chemical Co., Ltd.
    Inventors: Hiroshi Kobayashi, Yoshihiko Matsumoto, Tomohiro Okuda
  • Patent number: 11655216
    Abstract: In its many embodiments, the present invention provides certain substituted aryl and heteroaryl ether compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, L, R4, L1, Q, and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-? receptor (LXR?) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: May 23, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Michael T. Rudd, Zhaoyang Meng, Jenny Wai, David Jonathan Bennett, Edward J. Brnardic, Nigel J. Liverton, Shawn J. Stachel, Yongxin Han, Paul Tempest, Jiuxiang Zhu, Xuewang Xu, Bin Zhu